Skip to Content
MilliporeSigma
All Photos(1)

Documents

1288463

USP

Gemcitabine hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2′-Deoxy-2′,2′-difluorocytidine; dFdC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H11F2N3O4 · HCl
CAS Number:
122111-03-9
Molecular Weight:
299.66
MDL number:
MFCD01735988
UNSPSC Code:
41116107
PubChem Substance ID:
329749929

grade

pharmaceutical primary standard

API family

gemcitabine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

InChI key

OKKDEIYWILRZIA-OSZBKLCCSA-N

Gene Information

human ... POLA1(5422) , POLA2(23649) , POLD1(5424) , POLD2(5425) , POLD3(10714) , POLD4(57804) , POLE(5426) , POLE2(5427) , POLE3(54107) , PRIM1(5557) , PRIM2(5558) , RRM1(6240) , RRM2(6241) , RRM2B(50484)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

Application

It is intended to be used as a USP reference standard in specified quality tests and assays.
Also used to prepare standard solutions in the assay and impurities analysis using LC-UV as described in the following United States Pharmacopeia (USP) monographs:
  • Gemcitabine Hydrochloride
  • Gemcitabine for Injection

Biochem/physiol Actions

Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Capecitabine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1405

Capecitabine

Supelco

Supelco

PHR1883

Docetaxel

UNC0638 hydrate ≥98% (HPLC)

Sigma-Aldrich

U4885

UNC0638 hydrate

USP

USP

1224551

Docetaxel

Doxorubicin hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1225703

Doxorubicin hydrochloride

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Paclitaxel Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1803

Paclitaxel

Oxaliplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1528

Oxaliplatin

Carboplatin

Sigma-Aldrich

C2538

Carboplatin

Katsumi Fukamachi et al.
PloS one, 9(10), e111481-e111481 (2014-10-28)
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to
Erez Hasnis et al.
Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration
Jeffrey R Infante et al.
Investigational new drugs, 33(2), 432-439 (2015-02-03)
Background This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of gemcitabine, in combination with capecitabine, an oral pro-drug of 5-fluorouracil, in patients with advanced solid tumors. In addition, pharmacokinetics (PK) and
Minggen Hu et al.
Surgical endoscopy, 28(9), 2584-2591 (2014-04-08)
Laparoscopic distal splenopancreatectomy (DSP) is an effective and safe surgical modality for treating benign and borderline distal pancreatic tumors, but rarely for pancreatic cancer. This study aimed to examine the feasibility, effectiveness, and safety of laparoscopic versus laparotomic DSP in
Simone Limmer et al.
Pharmaceutical research, 31(9), 2276-2286 (2014-03-07)
The pyrimidine analogue gemcitabine (dFdC) is frequently used in the treatment of patients with solid tumors. However, after i.v. application dFdC is rapidly inactivated by metabolization. Here, the potential of thermosensitive liposomes based on 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2-TSL) were investigated as carrier
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service